Palisade Bio (FRA:7NS0) Short-Term Debt: €0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:7NS0 Palisade Bio Inc FRA:7NS0
33 GF Score
Price €5.01
! 2 Warning Signs
View Full Analysis

What is Palisade Bio Short-Term Debt?

Palisade Bio FRA:7NS0 33 Short-Term Debt is €0.00 Mil as of Jun. 2026. GuruFocus rates FRA:7NS0 with a GF Score™ of 33/100. The stock has 2 warning signs investors should review.

Palisade Bio's Short-Term Debt for the quarter that ended in Jun. 2026 was €0.00 Mil.

Palisade Bio's quarterly Short-Term Debt declined from Dec. 2025 (€0.06 Mil) to Mar. 2026 (€0.00 Mil) but then stayed the same from Mar. 2026 (€0.00 Mil) to Jun. 2026 (€0.00 Mil).

Palisade Bio's annual Short-Term Debt declined from Dec. 2023 (€0.15 Mil) to Dec. 2024 (€0.08 Mil) and declined from Dec. 2024 (€0.08 Mil) to Dec. 2025 (€0.06 Mil).

Palisade Bio Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Palisade Bio Short-Term Debt Related Terms

Palisade Bio Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Palisade Bio's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Palisade Bio Short-Term Debt Chart

Palisade Bio Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial 0.08 0.08 0.15 0.08 0.06

Palisade Bio Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.27 0.18 0.06 0.00 0.00
FRA:7NS0
33GF Score
Palisade Bio Inc FRA:7NS0
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of €0.00 Mil mean?
Palisade Bio (FRA:7NS0) has a Short-Term Debt of €0.00 Mil as of Jun. 2026.
Is Palisade Bio's Short-Term Debt too high?
Palisade Bio's current Short-Term Debt is €0.00 Mil. Overall, Palisade Bio has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Palisade Bio's Short-Term Debt compare to ABEO and RCKT?
Palisade Bio's Short-Term Debt of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Palisade Bio's current Short-Term Debt is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Palisade Bio stock overvalued right now?
Palisade Bio (FRA:7NS0) has a current Short-Term Debt of €0.00 Mil. The current Short-Term Debt is €0.00 Mil. Palisade Bio's overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Palisade Bio (FRA:7NS0), the current Short-Term Debt is €0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Palisade Bio Business Description

Other Exchanges PALI:USA
Address 4600 South Syracuse Street, Suite 900, Denver, CO, USA, 80237
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
33GF Score

Get the complete analysis for FRA:7NS0

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.01
Price